Drug intelligence / Profile preview

YH23537

Development stage: Phase 2
Lead developer: Yuhan
Administration: Oral

Overview

**YH23537** is an orally administered, process-optimized botanical combination developed by Yuhan. It contains extracts of Notoginseng Radix and Rehmanniae Radix Preparata and was designed to retain the chemical profile of YH14642 while improving extraction efficiency. Its pharmacology is characterized as anti-inflammatory: in lipopolysaccharide-stimulated human gingival fibroblasts, YH23537 reduced interleukin-6 and interleukin-8 secretion, but its direct molecular target or targets have not been established. It has completed Phase II studies in chronic periodontitis and knee osteoarthritis. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10163972/))

Other names: Notoginseng radix and rehmanniae radix preparata extract combination

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on YH23537.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YH23537.

Explore the full profile